Technical Analysis for KYTX - Kyverna Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 15.26 | 1.67% | 0.25 |
KYTX closed down 2.97 percent on Monday, April 29, 2024, on 2.58 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 1.67% | |
| Lower Bollinger Band Walk | Weakness | 1.67% | |
| New 52 Week Low | Weakness | 1.67% | |
| Wide Bands | Range Expansion | 1.67% | |
| Down 3 Days in a Row | Weakness | 1.67% | |
| Down 4 Days in a Row | Weakness | 1.67% | |
| Down 5 Days in a Row | Weakness | 1.67% | |
| Lower Bollinger Band Touch | Weakness | 1.67% | |
| Oversold Stochastic | Weakness | 1.67% | |
| New 52 Week Closing Low | Bearish | -1.36% |
| Alert | Time |
|---|---|
| Up 1% | 3 minutes ago |
| 60 Minute Opening Range Breakdown | about 22 hours ago |
| 2x Volume Pace | about 24 hours ago |
| 1.5x Volume Pace | about 24 hours ago |
| Down 5% | about 24 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Lupus Nephritis Sjögren Syndrome Systemic Sclerosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Autoimmune Disease Autoimmunity Multiple Sclerosis Lupus Rheumatology Myasthenia Gravis Lupus Nephritis Sjögren Syndrome Systemic Sclerosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.06 |
| 52 Week Low | 13.96 |
| Average Volume | 385,434 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 24.68 |
| 20-Day Moving Average | 20.72 |
| 10-Day Moving Average | 18.29 |
| Average True Range | 1.54 |
| RSI (14) | 23.08 |
| ADX | 46.36 |
| +DI | 7.81 |
| -DI | 44.16 |
| Chandelier Exit (Long, 3 ATRs) | 21.19 |
| Chandelier Exit (Short, 3 ATRs) | 18.57 |
| Upper Bollinger Bands | 26.64 |
| Lower Bollinger Band | 14.80 |
| Percent B (%b) | 0.02 |
| BandWidth | 57.16 |
| MACD Line | -2.55 |
| MACD Signal Line | -2.01 |
| MACD Histogram | -0.5344 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.77 | ||||
| Resistance 3 (R3) | 17.73 | 16.76 | 17.31 | ||
| Resistance 2 (R2) | 16.76 | 16.06 | 16.79 | 17.16 | |
| Resistance 1 (R1) | 15.89 | 15.63 | 15.41 | 15.93 | 17.00 |
| Pivot Point | 14.92 | 14.92 | 14.68 | 14.95 | 14.92 |
| Support 1 (S1) | 14.05 | 14.22 | 13.57 | 14.09 | 13.02 |
| Support 2 (S2) | 13.08 | 13.79 | 13.11 | 12.86 | |
| Support 3 (S3) | 12.21 | 13.08 | 12.71 | ||
| Support 4 (S4) | 12.25 |
